Ucb Patent-Cliff Exposure & CMS Drug Spending Portfolio
Ucb (US): 14 reconciled FDA prescription therapies (39.3% 2025 to 2030 cliff risk), $1.91B 2024 CMS Part D & Medicaid spend, and 79 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 14 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 39.3% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $1.91B |
| 2024 Medicare Part D Spend | $1.01B |
| 2024 Medicaid Spend | $895.6M |
| California HCAI SB 17 Filings | 79 WAC filings (max 20.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.